
DETECTION OF MUTATIONS IN THE CYP21A2 GENE:
GENOTYPE-PHENOTYPE CORRELATION IN
SLOVENIAN COUPLES WITH CONCEIVING PROBLEMS Stangler Herodež Š1,*, Fijavž L2, Zagradišnik B1, Kokalj Vokač N1,2 *Corresponding Author: Dr. Špela Stangler Herodež, Laboratory of Medical Genetics, University Clinical
Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia. Tel: +386-2-321-27-37. Fax: +386-2-321-27-55.
E-mail: spela.sh@ukc-mb.si page: 25 download article in pdf format
|
Abstract
The objective of this study was to compare the
CYP 21A2 genetic profiles of couples with unexplained
fertility problems (UFP) with genetic profiles
of healthy controls (HCs). Furthermore, we analyzed
associations between mutations in the CYP21A2 gene
and various clinical and laboratory parameters. Allele-
specific polymerase chain reaction (PCR) was
used in 638 probands with UFP and 200 HCs. Statistic
analysis with χ2 was used to study the association of
mutations with infertility. The effect of mutations
on particular clinical and laboratory parameters was
assessed with the analysis of variance (ANOVA) test.
With regard to the CYP21A2 gene, 0.6% of probands
with UFP and 0.5% of HCs were positive for the
c.290-13A/C>G mutation; 0.6% of probands with
UFP and 1.5% of HCs were positive for the p.I172N
mutation; there were no probands with UFP positive
for the p.P30L mutation, whereas 0.5% of HCs
were; and 0.2% of probands with UFP and 0.5%
of HCs were found to have the p.V281L mutation.
We found a significant association between c.290-
13A/C>G mutation and the frequency of significant
hormone deviations (χ2 = 6.997, p = 0.008). Similar
association was also observed between the c.290-
13A/C>G mutation and the frequency of polycystic
ovary syndrome (PCOS) (χ2 = 16.775, p = 0.000).
Our findings indicate that no significant difference
in the prevalence of CYP 21A2 mutations can be
found in probands with UFP when compared with
HCs without infertility history. The results also imply
the significant association of the c.290-13A/ C>G
mutation in the CYP21A2 gene, not only with the
frequency of PCOS, but also with the frequency of
significant hormone deviations.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|